Hrt Financial LP Adma Biologics, Inc. Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.4 - $6.74 $586,762 - $898,812	-133,355 Reduced 57.48%	98,656 $651,000
Q4 2023 Feb 09, 2024	SELL	$3.08 - $4.52 $53,884 - $79,077	-17,495 Reduced 7.01%	232,011 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$3.47 - $4.61 $176,525 - $234,519	50,872 Added 25.61%	249,506 $893,000
Q2 2023 Aug 11, 2023	BUY	$3.12 - $4.22 $619,738 - $838,235	198,634 New	198,634 $732,000
Q4 2022 Feb 10, 2023	BUY	$2.47 - $3.88 $1.53 Million - $2.41 Million	621,348 New	621,348 $2.41 Million
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.66 $128,727 - $196,044	-118,099 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $45,378 - $66,260	40,158 Added 51.52%	118,099 $133,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.07 $18,387 - $25,206	12,177 Added 18.52%	77,941 $124,000
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $109,825 - $194,003	65,764 New	65,764 $115,000
Q3 2020 Nov 13, 2020	SELL	$2.04 - $3.74 $23,415 - $42,927	-11,478 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $27,776 - $37,762	11,478 New	11,478 $33,000

318

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.62B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.